In vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb−drug interactions in the management of COVID-19

Ayurvedic medicines Withania somnifera Dunal (ashwagandha) and AYUSH-64 have been used for the prevention and management of COVID-19 in India. The present study explores the effect of Ashwagandha and AYUSH-64 on important human CYP enzymes (CYP3A4, CYP2C8, and CYP2D6) to assess their interaction wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Siva Swapna Kasarla (Author), Swapnil P. Borse (Author), Yashwant Kumar (Author), Neha Sharma (Author), Madhu Dikshit (Author)
Format: Book
Published: Frontiers Media S.A., 2022-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_eb85b8a9f70a4b0088ee7a96b3ce8891
042 |a dc 
100 1 0 |a Siva Swapna Kasarla  |e author 
700 1 0 |a Siva Swapna Kasarla  |e author 
700 1 0 |a Swapnil P. Borse  |e author 
700 1 0 |a Yashwant Kumar  |e author 
700 1 0 |a Neha Sharma  |e author 
700 1 0 |a Neha Sharma  |e author 
700 1 0 |a Madhu Dikshit  |e author 
700 1 0 |a Madhu Dikshit  |e author 
245 0 0 |a In vitro effect of Withania somnifera, AYUSH-64, and remdesivir on the activity of CYP-450 enzymes: Implications for possible herb−drug interactions in the management of COVID-19 
260 |b Frontiers Media S.A.,   |c 2022-10-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2022.973768 
520 |a Ayurvedic medicines Withania somnifera Dunal (ashwagandha) and AYUSH-64 have been used for the prevention and management of COVID-19 in India. The present study explores the effect of Ashwagandha and AYUSH-64 on important human CYP enzymes (CYP3A4, CYP2C8, and CYP2D6) to assess their interaction with remdesivir, a drug used for COVID-19 management during the second wave. The study also implies possible herb−drug interactions as ashwagandha and AYUSH-64 are being used for managing various pathological conditions. Aqueous extracts of ashwagandha and AYUSH-64 were characterized using LC-MS/MS. A total of 11 and 24 phytoconstituents were identified putatively from ashwagandha and AYUSH-64 extracts, respectively. In addition, in silico studies revealed good ADME properties of most of the phytoconstituents of these herbal drugs and suggested that some of these might possess CYP-450 inhibitory activity. In vitro CYP-450 studies with human liver microsomes showed moderate inhibition of CYP3A4, 2C8, and 2D6 by remdesivir, while ashwagandha had no inhibitory effect alone or in combination with remdesivir. AYUSH-64 also exhibited a similar trend; however, a moderate inhibitory effect on CYP2C8 was noticed. Thus, ashwagandha seems to be safe to co-administer with the substrates of CYP3A4, CYP2C8, and CYP2D6. However, caution is warranted in prescribing AYUSH-64 along with CYP2C8 substrate drugs. Furthermore, preclinical and clinical PK studies would be helpful for their effective and safer use in the management of various ailments along with other drugs. 
546 |a EN 
690 |a Withania somnifera 
690 |a Ayurveda 
690 |a remdesivir 
690 |a integrative medicine 
690 |a Rasayana 
690 |a LC-MS/MS 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 13 (2022) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2022.973768/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/eb85b8a9f70a4b0088ee7a96b3ce8891  |z Connect to this object online.